Visit
A three-part session with experts Solange Peters, Martin Reck, and Sanjay Popat, who discuss the latest updates in lung cancer…
The first interim results of the Phase III ADAURA study evaluating adjuvant osimertinib in stage IB-IIIA EGFR-mutated non-small cell lung…
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive gastrointestinal malignancy and is often associated with a poor prognosis. Surgery remains…
Seattle Genetics have announced the U.S. Food and Drug Administration (FDA) have granted approval for tucatinib in combination with trastuzumab…
April 15th saw the Food and Drug Administration (FDA) approval of mitomycin gel (Jelmyto) for the treatment of low-grade upper…
Clinical trials assessing the efficacy of pembrolizumab have previously enrolled patients with performance status (PS) 0–1. However, almost a fifth…
The first chimeric antigen receptor T-cell (CAR T-cell) therapy using chlorotoxin (CLTX), a toxin found in the venom of scorpions,…
Breast cancer is the most common type of malignancy in women.1 Human epidermal growth factor receptor 2 (HER2) positive breast…
Olaparib, a maintenance therapy for ovarian cancer, may prolong the benefit of initial treatment in BRCA1/2 mutated ovarian cancer patients…
Following the release of trial data, the FDA has approved erdafitinib for the treatment of adult patients with fibroblast growth…
It has been known for almost a century that thoracic radiotherapy can cause damage to the heart.[2] However, the first…
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest oncology news and updates
Keep up to date with all the latest news with our monthly newsletter